biostudies-literatureUnknown11(3)Deliwala SS<b>Background and study aims </b> Hemospray (TC-325) is a mineral powder with adsorptive properties designed for use in various gastrointestinal bleeding (GIB) scenarios. We conducted a systematic review & meta-analysis of randomized controlled trials (RCTs) comparing TC-325 to standard endoscopic therapy (SET) for non-variceal GIB (NVGIB). <b>Methods </b> Multiple databases were searched through October 2022. Meta-analysis was performed using a random-effects model to determine pooled relative risk (RR) and proportions with 95 % confidence intervals (CI) for primary hemostasis, hemostasis failure, 30-day rebleeding, length of stay (LOS), and need for rescue interventions. Heterogeneity was assessed using I ² %. <b>Results </b> Five RCTs with 362 patients (TC-325 178, SET 184) -Endoscopy international openE288-E295https://www.ebi.ac.uk/biostudies/studies/S-EPMC10038751biostudies-literatureHemostatic spray (TC-325) vs. standard endoscopic therapy for non-variceal gastrointestinal bleeding: A meta-analysis of randomized controlled trials.PMC10038751Chandan SAdler DDahiya DSMohan BPBapaye JAKassab LLRamai DFacciorusso AReddy NDeliwala SSKhan SChawla SfalseHemostatic spray (TC-325) vs. standard endoscopic therapy for non-variceal gastrointestinal bleeding: A meta-analysis of randomized controlled trials.<b>Background and study aims </b> Hemospray (TC-325) is a mineral powder with adsorptive properties designed for use in various gastrointestinal bleeding (GIB) scenarios. We conducted a systematic review & meta-analysis of randomized controlled trials (RCTs) comparing TC-325 to standard endoscopic therapy (SET) for non-variceal GIB (NVGIB). <b>Methods </b> Multiple databases were searched through October 2022. Meta-analysis was performed using a random-effects model to determine pooled relative risk (RR) and proportions with 95 % confidence intervals (CI) for primary hemostasis, hemostasis failure, 30-day rebleeding, length of stay (LOS), and need for rescue interventions. Heterogeneity was assessed using I ² %. <b>Results </b> Five RCTs with 362 patients (TC-325 178, SET 184) -2023-01-01T00:00:00Z2023 Mar2025-04-18T17:19:40.594Z2025-04-07T04:52:48.969ZS-EPMC100387513696897810.1055/a-2032-4199